Document:

Filed by Bowne Pure Compliance

Exhibit 10.1

November 1, 2005

Aart Brouwer

Seeburg Strasse 66

6006 Luzern

Switzerland

Dear Aart:

On behalf of Celgene International Sarl, I am pleased to extend an offer of employment to you as
President International, reporting to Robert Hugin. Your annual base compensation for this
position will be CHF 585,000 paid in monthly installments. In addition to your base compensation,
you will be eligible for a target bonus of 50% of your base salary, based on the achievement of
agreed upon performance objectives, in accordance with the provisions of our Management Incentive
Program. You will also be eligible for our Long Term Incentive Program (LTIP) with a target bonus
of 50% of your base salary, based on the Company achieving pre-defined performance objectives, in
accordance with the provisions of our Long Term Incentive Program (LTIP). The terms and conditions
of your employment will be subject to a three-year employment contract.

Aart, as we agreed, you will work in Neuchatel two days per week (projected on Monday and Tuesday)
and to the greatest extent possible we will remain cognizant of these dates when scheduling company
meetings and commitments. As agreed, we anticipate you will retain your principle residency in
Luzern.

You will be authorized to use the services of a company-paid car for your commute to Neuchatel for
these two days. Additionally, you will have full access to company paid housing for your overnight
stays in Neuchatel.

As we discussed we would like you to start in this position as soon as possible, and anticipate
your first day to be Wednesday, November 2, 2005.

As a new employee, you will be eligible for a one-time grant of 150,000 stock options of Celgene
common stock upon your employment start date. Grants are made at fair market value on the date of
the grant, and this grant will vest 100% upon grant issuance. Additionally, you will be eligible
for Celgene Corporation’s annual equity grant based upon performance.

 

 

 

Mr. Aart Brouwer

November 1, 2005

This confirms that you will participate in all Celgene International Sarl’s employee benefit
programs. Celgene International Sarl does require an employment physical examination, arrangements
for which will be coordinated with you. In addition, all employees are required to sign an
“Inventions and Confidential Information Agreement” upon the start of their employment. We also
request you complete the enclosed application for your personnel file.

Upon joining Celgene International Sarl, you will be eligible for four weeks vacation, and three
personal days within the calendar year, January 1 through December 31 as well as all public
holidays as set forth under Swiss requirements. Your vacation for the current year will be
prorated accordingly.

Aart, you bring a unique depth and breath of International experience needed at this very important
time for Celgene International Sarl. It is unquestionable that you will make a significant impact
on the future success of Celgene International Sarl, and we look forward to you becoming a part of
the senior leadership team.

If you have questions concerning any aspect of this offer, please contact me or Mary Weger. To
indicate your acceptance, sign below and return one copy of this letter to me.

Best regards,

Robert J. Hugin

SVP, Chief Financial Officer

	 	 	 
	I accept the offer as outlined above	 	 
	 
	 	 
	Anticipated start date	 	 

 

 

 

Mr. Aart Brouwer

November 1, 2005

EMPLOYMENT AGREEMENT

between

Celgene International Sârl,

(“Employer”)

and

Mr. Aart Brouwer,

(“Employee”)

	1.	 	Position and Responsibilities

	1.1	 	The Employer hereby employs the Employee and the Employee accepts employment as President
International.

	1.2	 	The Employee’s responsibilities are specified by the Employer. The Employee’s
responsibilities may, from time to time, be modified by the Employer to perform other
assignments or assume further responsibilities. The Employee’s other rights and obligations
shall not be affected by such modification.

	1.3	 	Unless the Employer provides otherwise, the Employee reports to Robert J. Hugin, President
and Chief Operating Officer. (designee)

	2.	 	Remuneration

	2.1	 	Salary

	 	 	The Employee shall receive an annual gross base salary of CHF 585,000 paid in 12 equal
installments to be paid on the final payday of each month.

	2.2	 	Bonus Payments

	 	 	In addition to the fixed base salary in accordance with paragraph 2.1 above, the Employee
shall be entitled to participate in the Management Incentive Plan (MIP) with an annual
target bonus of 50% of the Employee’s base salary based (to be calculated in local currency)
based on the achievement of agreed upon performance objectives, in accordance with the
provisions of the Employer’s Management Incentive Program and Celgene’s Long Term Incentive
Program (LTIP) with a target bonus of 50% of the Employee’s base salary, based on the
Company achieving pre-defined performance objectives, in accordance with the provisions or
our Long Term Incentive Program (LTIP).

 

 

 

Mr. Aart Brouwer

November 1, 2005

	2.3	 	Stock Options
	 
	 	 	As a new employee, pursuant to approval by the Compensation Committee of the Board
of Directors of Celgene Corporation, the Employee will receive a one-time grant of a stock
option to purchase 150’000 shares of Celgene common stock. Grants are made at fair market
value on the date of the grant, and this grant will vest 100% upon grant issuance.
Additionally, the Employee will be eligible for Celgene Corporation’s annual equity grant
based upon performance.
	 
	2.4	 	Deductions
	 
	 	 	The salary and bonus payments are gross payments. The Employee’s share in the prevailing
premiums for social security insurances mandatory under Swiss law such as “AHV”, “IV”,
“ALV”, “EO” etc., as well as for the pension plan maintained by the Employer (cf. paragraph.
4 hereafter) shall be deducted from the payments made to the Employee. In addition, the
Employee agrees he has provided to the Employer certification that he will not be required
to pay taxes at source. The Employee will himself have to report and pay taxes.
	 
	2.5	 	Further Payments
	 
	 	 	Unless otherwise expressly agreed upon in writing, the payment of any other gratuities,
profit shares, premiums or other extra payments shall be on a voluntary basis, subject to
the provision that even repeated payments without the reservation of voluntarily shall not
create any legal claim for the Employee, either in respect to their cause or their amount,
either for the past or for the future.
	 
	3.	 	Expenses
	 
	3.1	 	The Employer shall reimburse the Employee upon submission of appropriate vouchers for
reasonable and customary business travel expenses in accordance with the applicable Employer’s
guidelines as in force from time to time.
	 
	4.	 	Pension Fund
	 
	4.1	 	The Employee will be subject to the mandatory requirements of the Federal Law on Occupational
Old Age, Survivors and Disability Benefit Plan (“BVG”). Employer and Employee shall pay their
 shares in the pension plan according to the applicable pension regulations and the terms of
the pension plan administered by Winterthur
Columna or provider in place.

 

 

 

Mr. Aart Brouwer

November 1, 2005

	 
	5.	 	Sickness / Insurance, “EMPLOYEE’S PREVENTION FROM WORK”
	 
	5.1	 	If the Employee is by no fault of his own and due to reasons inherent in his person, such as
for example sickness, accident or military service, prevented from performing work, the
Employer will, after the first three months of employment, continue to pay the Employee’s
salary according to the following:

	 	 	 	 	 
	 

	 	1-90 days:
	 	100% of insured base salary
	 
	 	 	 	 
	 

	 	91-720 days:
	 	80% of insured base salary

	 	 	Nothing in this paragraph 5.3 shall in any way limit the parties’ freedom to give notice of
termination; once the employment terminated, the Employer shall no longer have the
obligation to make any salary payments but the Employee shall receive the benefits according
to the Pension Scheme, if any.
	 
	6.	 	Working Hours / Vacations
	 
	6.1	 	The Employee agrees to exercise his best efforts to successfully and carefully accomplish the
duties assigned to him
	 
	6.2	 	The Employee shall be entitled to 23 working days of paid vacations per calendar year, in
addition to public and bank holidays.
	 
	7.	 	Duties of Loyalty and Confidentiality
	 
	7.1	 	The Employee shall devote his efforts exclusively to the Employer in furtherance of the
Employer’s interests. Any engagement in additional occupations for remuneration or any
participation in any kind of enterprise requires the written consent of the Employer. This
shall not apply to the usual acquisition of stock or other shares for investment purposes.
Membership in the board of directors or supervisory board of other companies shall also
require the written approval of the Employer. The employee acknowledges the company policy
regarding Board of Director appointments of no more than two appointments so as to fully
ensure balance against outside Board commitments and Celgene objectives.
	 
	7.2	 	The Employee shall during the period of employment with the Employer and at any time
thereafter, keep secret any confidential information concerning the business, contractual
arrangements, deals, transactions or particular affairs of the Employer or its affiliates and
will not use any such information for his own benefit or the benefit of others. This
obligation shall also exist with respect to any protected data and confidential information of
third parties that the Employee gets to know while performing the obligations under this
Agreement.
	 
	7.3	 	Upon termination of this Agreement for any reason, the Employee shall return to the Employer
all files and any company documents concerning the business of the Employer and its affiliates
in his possession or open to his access, including all designs, customer and price lists,
printed material, documents, sketches, notes, drafts as well as copies thereof, regardless
whether or not the same are originally furnished by the Employer or its affiliates.
	 
	8.	 	Inventions
	 
	8.1.	 	 All intellectual property rights including but not limited to patent rights, design rights,
copyrights and related rights, database rights, trademark rights and chip rights as well as
any rights in know how ensuing from the work performed by the Employee during the term of his
employment (hereinafter the “Intellectual Property Rights”), shall exclusively vest in the
Employer. The Employee may not, without the Employer’s written consent, disclose, multiply,
use, manufacture, bring on the market or sell, lease, deliver or otherwise trade, offer, or
register the results of his work. Any inventions while performing the employment contract but
not in performance of a contractual obligation will be compensated appropriately (Art.332
paragraph. 4 CO)

 

 

 

Mr. Aart Brouwer

November 1, 2005

	8.2.	 	Insofar as rights that are mentioned in section 8.1 above and are related to the Intellectual
Property Rights are not vested in the Employer by operation of law or based on section 8.1
above, the Employee covenants that he will transfer and, insofar as possible, hereby transfers
to the Employer such rights provided, however, that the Employer may renounce such transfer or
transfer back to the Employee any such Intellectual Property Rights at any time. If a transfer
should not be possible under the applicable law, then the Employee shall grant to the Employer
a perpetual, transferable, royalty-free license to use such Intellectual Property Rights.
	 
	8.3	 	The Employer is entitled to transfer the Intellectual Property Rights in full or in part to
any third party. The Employer and such third parties are not obliged to mention the Employee
as the author if they publish any inventions, computer programs or other works. They are free
to make any modifications, translations and/or other adaptations and/or can refrain from
making any publications.
	 
	9.	 	Data Protection
	 
	 	 	With the execution of this Agreement, the Employee consents that the Employer may store,
transfer, adapt and delete all personal data in connection with this employment
relationship. The Employee acknowledges that personal data may be transferred to companies
outside Switzerland affiliated with the Employer, in particular to Celgene Corporation in
the U.S. However all such data transfer shall be guided to be in full compliance with Swiss
Data Protection Law.
	 
	10.	 	RESTRAINT OF COMPETITION
	 
	 	 	The Employee shall not, during the term of his employment and for a 12 months period after
the end of the employment, perform any activity competing with the Employer in specific
subject areas in which the Employee was active or to which he had access during his work for
Celgene.
	 
	 	 	In particular, the Employee agrees:

	 	•	 	not to have, directly or indirectly, any financial or other interest in a
business or company which develops, produces, markets or distributes products
substantially similar to the products of the Employer or its affiliated companies or to
render services similar to those rendered by the Employer or its affiliated companies
(a “Competitor”);

 

 

 

Mr. Aart Brouwer

November 1, 2005

	 	•	 	not to accept any part of full time employment in such a Competitor or to act
as consultant, agent or representative of or in any other capacity for such a
Competitor;
	 
	 	•	 	not to directly or indirectly establish such a Competitor.

	11.	 	SANCTIONS
	 
	 	 	The Employee understands that a violation of the obligations under article 10 of this
Agreement might cause serious damage to the Employer. In the event the Employee violates an
obligation under article 10 of this Agreement, the Employer shall be entitled to seek
judicial enforcement of such obligation. Furthermore, the Employee agrees to pay to the
Employer an amount of CHF 585’000 as liquidated damages upon each violation of a duty or
obligation under article 10. The payment of the liquidated damages does not relieve the
Employee from the obligations under article 10 of this Agreement. The Employer’s right to
claim damages exceeding the amount of liquidated damages is expressly reserved.
	 
	12.	 	Duration and Termination
	 
	12.1	 	This Employment Agreement shall be effective as of November 2, 2005 and last for a fixed
period of three years terminating, without any notice being required, on November 1, 2008.
	 
	12.2	 	The first three months of the employment relationship shall be the probation period. During
the probation period, this Agreement may be terminated by either party at any time by
respecting notice period of seven days.
	 
	12.3	 	After the end of the probation period this Agreement may be terminated by either party by
respecting a notice period of three months in the fourth, fifth and sixth month of service and
thereafter by respecting a notice period of six months always with effect to the end of a
calendar month.
	 
	13.	 	Miscellaneous
	 
	13.1	 	This Employment Agreement replaces all prior understandings and/or contracts between the
parties.
	 
	13.2	 	Amendments and additions to this Agreement including this clause must be in writing to be
effective. This form requirement does not apply to the notice of termination, which does not
require a particular form.

 

 

 

Mr. Aart Brouwer

November 1, 2005

	13.3	 	Should one or several provisions of this Agreement prove invalid, in part or in whole, such
invalid provision(s) shall not affect the validity of the other provisions in this Agreement.
The invalid provision(s) shall be replaced by such valid provision(s) that best meet(s) the
parties’ intention when agreeing on the invalid provision(s).
	 
	14.	 	Applicable Law
	 
	14.1	 	This Employment Agreement shall be governed by Swiss law.

Celgene International Sàrl

by: The Employee

	 	 	 	 	 	 	 
	 

Aart Brouwer

	 	 	 	 

Place/Date
	 	 
	 
	 	 	 	 	 	 
	by: The Employer
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

Robert J. Hugin

	 	 	 	 

Place/DateFiled by Bowne Pure Compliance

Exhibit 10.2

June 2, 2003

Dr. Graham Burton

45 Gaitway Drive

Skillman, New Jersey 08558

Dear Graham:

On behalf of Celgene Corporation, I am pleased to extend an offer of employment to you as Senior
Vice President, Regulatory Affairs and Pharmacovigilance, reporting directly to me. Your annual
compensation for this position will be $375,000, paid in semi-monthly installments. We would like
you to start in this position as soon as possible, given your obligations to your current employer.
This offer is contingent upon the satisfactory completion of references.

In addition to your base compensation, you will be eligible for a target bonus of 40% of your base
salary, based on the achievement of agreed upon performance objectives, to be prorated for the
length of time in the position, in accordance with the provisions of our Management Incentive
Program. You will also be eligible to participate in Celgene’s Deferred Compensation Plan. In
addition, you will be eligible to participate in Celgene’s Long Term Incentive Plan for which the
first pay out is in 2005 contingent upon achievement of established goals. The LTIP target at 100%
is 0.5x of base with a maximum payout at 200% of 1x base.

As a new employee, pursuant to approval by the Compensation Committee of the Board of Directors,
you will be eligible for a one-time grant of 50,000 stock options of Celgene common stock upon your
employment start date. You will also, in this position, be eligible for an annual grant target of
20,000 options, subject to corporate and individual performance. Grants are made at fair market
value on the date of the grant, vesting in equal parts over four years.

Upon joining Celgene, you will be eligible for four weeks vacation, and three personal days.
Additionally, we have agreed to provide a one-time sign-on bonus, which will be paid within thirty
days of your start date in the amount of $20,000, less applicable taxes and withholdings.

Our offer provides for participation in Celgene’s employee benefit program following 30 days of
employment, a summary of which is enclosed. Celgene does require an employment physical
examination, arrangements for which may be made through Colleen Greenberg at (732) 805-3741. In
addition, all employees are required to sign an “Inventions and Confidential Information Agreement”
upon the start of their employment. Current Federal regulations also require you to furnish proof
of your right to work in the United States as outlined in the enclosed
federal form I-9. These documents must be submitted on your first day of work. We also request
you complete the enclosed application for your personnel file.

 

 

 

If your employment is terminated by Celgene at any time, other than for cause, we will pay you
severance compensation in an amount equal to twelve months base salary, less applicable taxes.

Graham, you bring a unique diversity of experience highly relevant to Celgene, a demonstrated track
record of results and finally, it was apparent to all that met you, that your leadership
competencies will be a strong addition to Celgene. It is unquestionable that you will make a
significant impact on the future success of Celgene, and we look forward to you becoming a part of
the leadership team.

If you have questions concerning any aspect of this offer, please contact me. To indicate your
acceptance, sign below and return one copy of this letter to me.

Best Regards,

Sol J. Barer, PhD

President and Chief Operating Officer

	 	 	 
	 	 	 
	I accept the offer as outlined above
	 	 
	 
	 	 
	 	 	 
	Anticipated start date

	 	 

	 	 	 
	1	 	This letter is not, and should not be interpreted as, an express or implied
contract of employment. At all times employment with Celgene is at will.

 

 

 

AMENDMENT TO GRAHAM BURTON EMPLOYMENT LETTER AGREEMENT

Celgene Corporation (“Celgene” or “Company”) and Dr. Graham Burton (“Burton”) hereby enter into
this agreement to amend the employment letter agreement between Burton and Celgene dated June 2,
2003 and executed on or about June 3, 2003 (“Letter Agreement”). The purpose of this amendment is
to amend Dr. Burton’s Letter Agreement as follows: (i) to define the meaning of the terms “cause”
and “change in control” and (ii) to include bonus in the severance calculation and 12 months of
COBRA benefit coverage for both health and dental insurance in the event of certain terminations.

The parties agree that for purposes of the Burton letter agreement, “cause” shall mean:

	 	•	 	the conviction of a crime involving moral turpitude or a felony;
	 
	 	•	 	acts or omissions taken in bad faith and to the detriment of the Company; or
	 
	 	•	 	a breach of any material term of the letter agreement.

The parties also agree that for purposes of the Burton Letter Agreement, “change in control” shall
mean a “change in control” as defined in Section 11.2 of the Company’s 1998 Stock Incentive Plan
(as in effect on the date hereof).

If Dr. Burton’s employment is terminated by the Company at any time other than for “cause” or his
employment is terminated by the Company for any reason on or following a “change in control” of the
Company, in each case, Dr. Burton would receive the following payments and benefits: (i) a lump sum
payment equal to 12 months base salary and bonus, less applicable taxes and (ii) 12 months of
Company-paid COBRA benefit coverage for health and dental insurance, subject to Dr. Burton’s
payment of premiums at the applicable active rate (at a coverage level equal to or below elected
coverage on the day before the termination date).

By signing below, each party acknowledges that it has read and understands the terms of this
amendment to the letter agreement and agrees to be bound as stated herein. This amendment was
executed on April 28, 2008.

	 	 	 	 	 
	Dr. Graham Burton

	 	Celgene Corporation	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	By: Sol J. Barer, Ph.D.	 	 
	 

	 	Chairman of the Board and
Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]